+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product (Highly Potent API, Antibody Drug Conjugate), By Synthesis, By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 150 Pages
  • September 2023
  • Region: Global
  • Grand View Research
  • ID: 5893298
Description Jump to:

Quick Summary:

In a fast-evolving global healthcare landscape, the active pharmaceutical ingredient (API) contract development and manufacturing organization (CDMO) market offers unique opportunities. Driven by factors such as increased pharmaceutical R&D investments, rising demand for generic drugs and biologic innovations, patent expirations and the growing complexity of APIs, this market is primed for expansion. Global scale and reach remain challenging in this still fragmented sector, with few companies achieving extensive international presence. However, many are now offering one-stop-shop solutions, effectively integrating API and formulation sources.

The need to enhance efficiencies, broaden regional presence, reduce resource costs, acquire therapeutic expertise and improve on-demand services has seen outsourcing become a highly viable solution for many pharmaceutical entities. Additionally, API CDMOs where expected to quickly adapt to maintain drug supply under unprecedented expectations. Future growth is anticipated, spurred on by global demand for new therapies and increased clinical research.

The global active pharmaceutical ingredient CDMO market size is expected to reach USD 156.3 billion by 2030. The market is expected to expand at a CAGR of 6.9% from 2023 to 2030. Increasing pharmaceutical R&D investments, patent expirations, and a rise in demand for generic drugs and biologic innovations propelling outsourcing are the factors driving the market.

The growth of small molecules, rising active pharmaceutical ingredient (API) complexity and the need to reduce costs are factors contributing to the rapid expansion of outsourcing services in the pharmaceutical sector. Only a few companies have achieved global reach and scale in the contract development and manufacturing organization (CDMO) sector, which is still fragmented. Besides, many companies are providing one-stop-shop solutions as an integrated source of APIs and formulations.

As the healthcare industry is undergoing a process of dynamic change, factors such as rapid technological advancements (e.g., automation & AI), the need for CROs/CMOs/CDMOs, and rising investments in research are influencing the healthcare market. The outsourcing of activities is benefitting many pharmaceutical companies in improving their operational efficiencies, expanding their geographical presence, decreasing resource costs, gaining therapeutic expertise, and enhancing on-demand services.

The COVID-19 pandemic placed unprecedented expectations on API makers, as evidenced by the substantial increase in demand for medications required to manage critically ill patients on mechanical ventilation. As a result, the sudden need to rapidly increase production has emphasized the need for adaptability for API CDMOs in maintaining drug supply, with some companies proving to be better prepared to withstand the pressures of quick scale-up than others. Growing demand for new therapies worldwide and an increase in the conduction of clinical research in the post-pandemic period are expected to support the market in the coming years.

Active Pharmaceutical Ingredient CDMO Market Report Highlights

  • The traditional active pharmaceutical ingredient segment dominated the market and accounted for the largest revenue share of 39.8% in 2022, due to the high adoption of traditional API in majority of pharmaceuticals
  • The innovative drugs segment held 73.7% of the revenue share in 2022. This is largely attributed to increasing FDA approvals for new molecular entities, and the increased focus on R&D by innovator API companies
  • The oncology segment led the market with the highest revenue share of 35.5% in 2022. This is due to the increasing demand for highly potent APIs for cancer therapy
  • The biotech segment is expected to grow at the fastest rate of 7.0% over the forecast period, owing to the high adoption of biopharmaceuticals in the treatment of chronic and infectious diseases
  • The clinical workflow segment is anticipated to witness the fastest CAGR of 7.3% over the forecast period. An increase in the number of clinical research studies supporting the demand for APIs is one of the key factors driving segment growth
  • In Asia Pacific, the market is expected to register the fastest CAGR of 9.1% over the forecast period. Due to the extreme growth in the number of pharmaceutical companies and contract manufacturing organizations in developing countries such as India and China, the region is likely to overtake Europe and North America in the near future


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Active Pharmaceutical Ingredient CDMO Market

What is the estimated value of the Global Active Pharmaceutical Ingredient CDMO Market?

The Global Active Pharmaceutical Ingredient CDMO Market was estimated to be valued at $92.1 Billion in 2022.

What is the growth rate of the Global Active Pharmaceutical Ingredient CDMO Market?

The growth rate of the Global Active Pharmaceutical Ingredient CDMO Market is 6.9%, with an estimated value of $156.3 Billion by 2030.

What is the forecasted size of the Global Active Pharmaceutical Ingredient CDMO Market?

The Global Active Pharmaceutical Ingredient CDMO Market is estimated to be worth $156.3 Billion by 2030.

Who are the key companies in the Global Active Pharmaceutical Ingredient CDMO Market?

Key companies in the Global Active Pharmaceutical Ingredient CDMO Market include Cambrex Corporation, Recipharm AB, Thermo Fisher Scientific Inc. (Pantheon), Samsung Biologics, Lonza, Catalent, Inc., Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim and CordenPharma International.
Report AttributeDetails
No. of Pages150
PublishedSeptember 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 92.1 Billion
Forecasted Market Value ( USD ) by 2030 $ 156.3 Billion
Compound Annual Growth Rate6.9%
Regions CoveredGlobal
No. of Companies Mentioned10

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Synthesis
1.1.3. Drug
1.1.4. Application
1.1.5. Workflow
1.1.6. Regional scope
1.1.7. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Volume price analysis (Model 2)
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
1.9.3. Objective 3
1.9.4. Objective 4
Chapter 2. Executive Summary
2.1. Market Outlook
Chapter 3. Active Pharmaceutical Ingredients CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Increasing pharmaceutical R&D investment
3.3.1.2. Rising demand for generic drugs
3.3.1.3. Patent expiration
3.3.1.4. Expanding consumption of biopharmaceuticals
3.3.2. Market Restraint Analysis
3.3.2.1. Compliance issues while outsourcing
3.3.3. COVID-19 Impact & Recovery Analysis
3.3.4. Industry Analysis - Porter’s Five Forces
3.3.5. PESTLE Analysis
Chapter 4. Active Pharmaceutical Ingredients CDMO Market: Product Segment Analysis
4.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
4.2. Active Pharmaceutical Ingredients CDMO Market: Product Market Share Analysis, 2022 & 2030
4.3. Traditional Active Pharmaceutical Ingredient (Traditional API)
4.3.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market, 2018 - 2030 (USD Million)
4.4. Highly Potent Active Pharmaceutical Ingredient (HP-API)
4.4.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market, 2018 - 2030 (USD Million)
4.5. Antibody Drug Conjugate (ADC)
4.5.1. Antibody Drug Conjugate (ADC) Market, 2018 - 2030 (USD Million)
4.6. Others
4.6.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Active Pharmaceutical Ingredients CDMO Market: Synthesis Segment Analysis
5.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
5.2. Active Pharmaceutical Ingredients CDMO Market: Synthesis Market Share Analysis, 2022 & 2030
5.3. Synthetic
5.3.1. Synthetic Market, 2018 - 2030 (USD Million)
5.4. Biotech
5.4.1. Biotech Market, 2018 - 2030 (USD Million)
Chapter 6. Active Pharmaceutical Ingredients CDMO Market: Drug Segment Analysis
6.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
6.2. Active Pharmaceutical Ingredients CDMO Market: Drug Market Share Analysis, 2022 & 2030
6.3. Innovative
6.3.1. Innovative Market, 2018 - 2030 (USD Million)
6.4. Generic
6.4.1. Generic Market, 2018 - 2030 (USD Million)
Chapter 7. Active Pharmaceutical Ingredients CDMO Market: Workflow Segment Analysis
7.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
7.2. Active Pharmaceutical Ingredients CDMO Market: Workflow Market Share Analysis, 2022 & 2030
7.3. Clinical
7.3.1. Clinical Market, 2018 - 2030 (USD Million)
7.4. Commercial
7.4.1. Commercial Market, 2018 - 2030 (USD Million)
Chapter 8. Active Pharmaceutical Ingredients CDMO Market: Application Segment Analysis
8.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
8.2. Active Pharmaceutical Ingredients CDMO Market: Application Market Share Analysis, 2022 & 2030
8.3. Oncology
8.3.1. Oncology Market, 2018 - 2030 (USD Million)
8.4. Hormonal
8.4.1. Hormonal Market, 2018 - 2030 (USD Million)
8.5. Glaucoma
8.5.1. Glaucoma Market, 2018 - 2030 (USD Million)
8.6. Cardiovascular
8.6.1. Cardiovascular Market, 2018 - 2030 (USD Million)
8.7. Diabetes
8.7.1. Diabetes Market, 2018 - 2030 (USD Million)
8.8. Others
8.8.1. Others Market, 2018 - 2030 (USD Million)
Chapter 9. Active Pharmaceutical Ingredients CDMO Market: Regional Analysis
9.1. Active Pharmaceutical Ingredients CDMO Regional market share analysis, 2022 & 2030
9.2. North America
9.2.1. North America Market estimates and forecast, 2018 - 2030
9.2.2. U.S.
9.2.2.1. U.S. Market estimates and forecast, 2018 - 2030
9.2.3. Canada
9.2.3.1. Canada Market estimates and forecast, 2018 - 2030
9.3. Europe
9.3.1. Europe Market estimates and forecast, 2018 - 2030
9.3.2. UK
9.3.2.1. UK Market estimates and forecast, 2018 - 2030
9.3.3. Germany
9.3.3.1. Germany Market estimates and forecast, 2018 - 2030
9.3.4. France
9.3.4.1. France Market estimates and forecast, 2018 - 2030
9.3.5. Italy
9.3.5.1. Italy Market estimates and forecast, 2018 - 2030
9.3.6. Spain
9.3.6.1. Spain Market estimates and forecast, 2018 - 2030
9.3.7. Denmark
9.3.7.1. Denmark Market estimates and forecast, 2018 - 2030
9.3.8. Sweden
9.3.8.1. Sweden Market estimates and forecast, 2018 - 2030
9.3.9. Norway
9.3.9.1. Norway Market estimates and forecast, 2018 - 2030
9.4. Asia Pacific
9.4.1. Asia Pacific Market estimates and forecast, 2018 - 2030
9.4.2. Japan
9.4.2.1. Japan Market estimates and forecast, 2018 - 2030
9.4.3. China
9.4.3.1. China Market estimates and forecast, 2018 - 2030
9.4.4. India
9.4.4.1. India Market estimates and forecast, 2018 - 2030
9.4.5. South Korea
9.4.5.1. South Korea Market estimates and forecast, 2018 - 2030
9.4.6. Australia
9.4.6.1. Australia Market estimates and forecast, 2018 - 2030
9.4.7. Thailand
9.4.7.1. Thailand Market estimates and forecast, 2018 - 2030
9.5. Latin America
9.5.1. Latin America Market estimates and forecast, 2018 - 2030
9.5.2. Brazil
9.5.2.1. Brazil Market estimates and forecast, 2018 - 2030
9.5.3. Mexico
9.5.3.1. Mexico Market estimates and forecast, 2018 - 2030
9.5.4. Argentina
9.5.4.1. Argentina Market estimates and forecast, 2018 - 2030
9.5.5. Colombia
9.5.5.1. Colombia Market estimates and forecast, 2018 - 2030
9.5.6. Chile
9.5.6.1. Chile Market estimates and forecast, 2018 - 2030
9.6. MEA
9.6.1. MEA Market estimates and forecast, 2018 - 2030
9.6.2. South Africa
9.6.2.1. South Africa Market Estimates and forecast, 2018 - 2030
9.6.3. Saudi Arabia
9.6.3.1. Saudi Arabia Market estimates and forecast, 2018 - 2030
9.6.4. UAE
9.6.4.1. UAE Market estimates and forecast, 2018 - 2030
9.6.5. Kuwait
9.6.5.1. Kuwait Market estimates and forecast, 2018 - 2030
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Strategy Mapping
10.3. Company Profiles/Listing
10.3.1. Cambrex Corporation
10.3.1.1. Overview
10.3.1.2. Financial Performance
10.3.1.3. Service Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Recipharm AB
10.3.2.1. Overview
10.3.2.2. Financial Performance
10.3.2.3. Service Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. Thermo Fisher Scientific Inc. (Pantheon)
10.3.3.1. Overview
10.3.3.2. Financial Performance
10.3.3.3. Service Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. Samsung Biologics
10.3.4.1. Overview
10.3.4.2. Financial Performance
10.3.4.3. Service Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Lonza
10.3.5.1. Overview
10.3.5.2. Financial Performance
10.3.5.3. Service Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Catalent, Inc.
10.3.6.1. Overview
10.3.6.2. Financial Performance
10.3.6.3. Service Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. Siegfried Holding AG
10.3.7.1. Overview
10.3.7.2. Financial Performance
10.3.7.3. Service Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Piramal Pharma Solutions
10.3.8.1. Overview
10.3.8.2. Financial Performance
10.3.8.3. Service Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Boehringer Ingelheim
10.3.9.1. Overview
10.3.9.2. Financial Performance
10.3.9.3. Service Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. CordenPharma International
10.3.10.1. Overview
10.3.10.2. Financial Performance
10.3.10.3. Service Benchmarking
10.3.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 4 Global active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 5 Global active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 6 Global active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 7 Global active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 8 Global active pharmaceutical ingredient CDMO market, by region, 2018 - 2030 (USD Million)
Table 9 North America active pharmaceutical ingredient CDMO market, by country, 2018 - 2030 (USD Million)
Table 10 North America active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 11 North America active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 12 North America active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 13 North America active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 14 North America active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 15 U.S. active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 16 U.S. active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 17 U.S. active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 18 U.S. active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 19 U.S. active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 20 Canada active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 21 Canada active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 22 Canada active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 23 Canada active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 24 Canada active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 25 Europe active pharmaceutical ingredient CDMO market, by country, 2018 - 2030 (USD Million)
Table 26 Europe active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 27 Europe active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 28 Europe active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 29 Europe active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 30 Europe active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 31 Germany active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 32 Germany active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 33 Germany active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 34 Germany active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 35 Germany active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 36 UK active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 37 UK active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 38 UK active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 39 UK active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 40 UK active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 41 France active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 42 France active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 43 France active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 44 France active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 45 France active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 46 Italy active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 47 Italy active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 48 Italy active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 49 Italy active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 50 Italy active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 51 Spain active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 52 Spain active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 53 Spain active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 54 Spain active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 55 Spain active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 56 Denmark active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 57 Denmark active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 58 Denmark active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 59 Denmark active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 60 Denmark active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 61 Sweden active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 62 Sweden active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 63 Sweden active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 64 Sweden active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 65 Sweden active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 66 Norway active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 67 Norway active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 68 Norway active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 69 Norway active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 70 Norway active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 71 Asia Pacific active pharmaceutical ingredient CDMO market, by country, 2018 - 2030 (USD Million)
Table 72 Asia Pacific active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 73 Asia Pacific active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 74 Asia Pacific active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 75 Asia Pacific active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 76 Asia Pacific active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 77 Japan active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 78 Japan active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 79 Japan active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 80 Japan active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 81 Japan active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 82 China active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 83 China active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 84 China active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 85 China active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 86 China active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 87 India active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 88 India active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 89 India active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 90 India active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 91 India active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 92 Australia active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 93 Australia active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 94 Australia active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 95 Australia active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 96 Australia active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 97 South Korea active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 98 South Korea active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 99 South Korea active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 100 South Korea active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 101 South Korea active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 102 Thailand active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 103 Thailand active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 104 Thailand active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 105 Thailand active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 106 Thailand active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million
Table 107 Latin America active pharmaceutical ingredient CDMO market, by country, 2018 - 2030 (USD Million)
Table 108 Latin America active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 109 Latin America active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 110 Latin America active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 111 Latin America active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 112 Latin America active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 113 Brazil active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 114 Brazil active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 115 Brazil active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 116 Brazil active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 117 Brazil active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 118 Mexico active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 119 Mexico active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 120 Mexico active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 121 Mexico active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 122 Mexico active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 123 Argentina active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 124 Argentina active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 125 Argentina active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 126 Argentina active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 127 Argentina active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 128 Colombia active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 129 Colombia active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 130 Colombia active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 131 Colombia active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 132 Colombia active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 133 Chile active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 134 Chile active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 135 Chile active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 136 Chile active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 137 Chile active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 138 Middle East & Africa active pharmaceutical ingredient CDMO market, by country, 2018 - 2030 (USD Million)
Table 139 Middle East & Africa active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 140 Middle East & Africa active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 141 Middle East & Africa active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 142 Middle East & Africa active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 143 Middle East & Africa active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 144 South Africa active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 145 South Africa active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 146 South Africa active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 147 South Africa active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 148 South Africa active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 149 Saudi Arabia active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 150 Saudi Arabia active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 151 Saudi Arabia active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 152 Saudi Arabia active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 153 Saudi Arabia active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 154 UAE active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 155 UAE active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 156 UAE active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 157 UAE active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 158 UAE active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 159 Kuwait active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 160 Kuwait active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 161 Kuwait active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 162 Kuwait active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 163 Kuwait active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Active Pharmaceutical Ingredients CDMO market snapshot (2020)
Fig. 8 Active Pharmaceutical Ingredients CDMO market segmentation
Fig. 9 Parent market outlook
Fig. 10 Penetration & growth prospect mapping
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 FDA approval and biosimilar product launch trends from 2015 to 2020.
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Porter’s Five Forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Active Pharmaceutical Ingredients CDMO market Product outlook: Segment dashboard
Fig. 17 Active Pharmaceutical Ingredients CDMO market: Product movement analysis
Fig. 18 Traditional API market, 2018 - 2030 (USD Million)
Fig. 19 HP-API market, 2018 - 2030 (USD Million)
Fig. 20 Antibody-drug conjugate market, 2018 - 2030 (USD Million)
Fig. 21 Others market, 2018 - 2030 (USD Million)
Fig. 22 Active Pharmaceutical ingredients CDMO market synthesis outlook: segment dashboard
Fig. 23 Active pharmaceutical ingredients CDMO market: synthesis movement analysis
Fig. 24 Synthetic market, 2018 - 2030 (USD Million)
Fig. 25 Biotech market, 2018 - 2030 (USD Million)
Fig. 26 Active pharmaceutical ingredients CDMO market drug outlook: segment dashboard
Fig. 27 Active pharmaceutical ingredients CDMO market: drug movement analysis
Fig. 28 Innovative market, 2018 - 2030 (USD Million)
Fig. 29 Generics market, 2018 - 2030 (USD Million)
Fig. 30 Active pharmaceutical ingredients CDMO market application outlook: segment dashboard
Fig. 31 Active pharmaceutical ingredients CDMO market: application movement analysis
Fig. 32 Oncology market, 2018 - 2030 (USD Million)
Fig. 33 Hormonal market, 2018 - 2030 (USD Million)
Fig. 34 Glaucoma market, 2018 - 2030 (USD Million)
Fig. 35 Cardiovascular disease market, 2018 - 2030 (USD Million)
Fig. 36 Diabetes market, 2018 - 2030 (USD Million)
Fig. 37 Others market, 2018 - 2030 (USD Million)
Fig. 38 Active pharmaceutical ingredients CDMO market workflow outlook: segment dashboard
Fig. 39 Active pharmaceutical ingredients CDMO market: workflow movement analysis
Fig. 40 Clinical market, 2018 - 2030 (USD Million)
Fig. 41 Commercial market, 2018 - 2030 (USD Million)
Fig. 42 Regional market: Key takeaways
Fig. 43 Active Pharmaceutical Ingredients CDMO market: Regional movement analysis
Fig. 44 North America market, 2018 - 2030 (USD Million)
Fig. 45 U.S. market, 2018 - 2030 (USD Million)
Fig. 46 Canada market, 2018 - 2030 (USD Million)
Fig. 47 Europe market, 2018 - 2030 (USD Million)
Fig. 48 UK market, 2018 - 2030 (USD Million)
Fig. 49 Germany market, 2018 - 2030 (USD Million)
Fig. 50 France market, 2018 - 2030 (USD Million)
Fig. 51 Italy market, 2018 - 2030 (USD Million)
Fig. 52 Spain market, 2018 - 2030 (USD Million)
Fig. 53 Denmark market, 2018 - 2030 (USD Million)
Fig. 54 Sweden market, 2018 - 2030 (USD Million)
Fig. 55 Norway market, 2018 - 2030 (USD Million)
Fig. 56 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 57 India market, 2018 - 2030 (USD Million)
Fig. 58 Japan market, 2018 - 2030 (USD Million)
Fig. 59 China market, 2018 - 2030 (USD Million)
Fig. 60 Australia market, 2018 - 2030 (USD Million)
Fig. 61 South Korea market, 2018 - 2030 (USD Million)
Fig. 62 Thailand market, 2018 - 2030 (USD Million)
Fig. 63 Latin America market, 2018 - 2030 (USD Million)
Fig. 64 Brazil market, 2018 - 2030 (USD Million)
Fig. 65 Mexico market, 2018 - 2030 (USD Million)
Fig. 66 Argentina market, 2018 - 2030 (USD Million)
Fig. 67 Colombia market, 2018 - 2030 (USD Million)
Fig. 68 Chile market, 2018 - 2030 (USD Million)
Fig. 69 MEA market, 2018 - 2030 (USD Million)
Fig. 70 South Africa market, 2018 - 2030 (USD Million)
Fig. 71 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 72 UAE market, 2018 - 2030 (USD Million)
Fig. 73 Kuwait market, 2018 - 2030 (USD Million)

Companies Mentioned

  • Cambrex Corporation
  • Recipharm AB
  • Thermo Fisher Scientific Inc. (Pantheon)
  • Samsung Biologics
  • Lonza
  • Catalent, Inc.
  • Siegfried Holding AG
  • Piramal Pharma Solutions
  • Boehringer Ingelheim
  • CordenPharma International

Methodology

Loading
LOADING...

Related Topics

Related Reports

Global Clinical Research Services Market by Services (Clinical Trials, Diagnostic Research, Drug Development Consultancy), Indication (Cardio Vascular Disorders, CNS Disorders, Diabetes), End-User, Deployment - Forecast 2023-2030 - Product Image

Global Clinical Research Services Market by Services (Clinical Trials, Diagnostic Research, Drug Development Consultancy), Indication (Cardio Vascular Disorders, CNS Disorders, Diabetes), End-User, Deployment - Forecast 2023-2030

  • Report
  • 197 Pages
  • Global
From
Pharmaceutical Intermediates Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028) - Product Image

Pharmaceutical Intermediates Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

  • Report
  • 110 Pages
  • Global
From
Drug Discovery Global Market Report 2023 - Product Image

Drug Discovery Global Market Report 2023

  • Report
  • 200 Pages
  • Global
From
Global Active Pharmaceutical Ingredients CDMO Market (API-CDMO) by Drug (Generics, Innovative), Product (Antibody Drug Conjugate, Highly Potent Active Pharmaceutical Ingredient, Traditional Active Pharmaceutical Ingredient), Synthesis, Workflow, Application - Forecast 2023-2030 - Product Image

Global Active Pharmaceutical Ingredients CDMO Market (API-CDMO) by Drug (Generics, Innovative), Product (Antibody Drug Conjugate, Highly Potent Active Pharmaceutical Ingredient, Traditional Active Pharmaceutical Ingredient), Synthesis, Workflow, Application - Forecast 2023-2030

  • Report
  • 194 Pages
  • Global
From
Active Pharmaceutical Ingredients CDMO Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028) - Product Image

Active Pharmaceutical Ingredients CDMO Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

  • Report
  • 115 Pages
  • Global
From
Copyright © 2002-2023 Research and Markets. All Rights Reserved.